EthiopiaTuberculosis profile
Population  2017 105 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 25 (16–37) 24 (15–35)
Mortality (HIV+TB only) 3.6 (2.5–5) 3.5 (2.4–4.8)
Incidence  (includes HIV+TB) 172 (121–232) 164 (115–221)
Incidence (HIV+TB only) 12 (8.6–17) 12 (8.2–16)
Incidence (MDR/RR-TB)** 5.5 (2.9–8.9) 5.2 (2.8–8.4)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 9.5 (8.7–10) 69 (55–83) 78 (61–95)
Males 10 (9.6–11) 83 (65–102) 94 (71–116)
Total 20 (18–22) 152 (106–198) 172 (121–232)
TB case notifications, 2017  
Total cases notified 117 705
Total new and relapse 116 725
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 86%
          - % pulmonary 69%
          - % bacteriologically confirmed among pulmonary 58%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 68% (50–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.17 (0.1–0.26)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 7 272 7%
          - on antiretroviral therapy 6 673 92%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  2 700
(1 700–3 700)
Estimated % of TB cases with MDR/RR-TB 2.7% (1.6–4.1) 14% (6.7–25)  
% notified tested for rifampicin resistance     38 501
MDR/RR-TB cases tested for resistance to second-line drugs   205
Laboratory-confirmed cases MDR/RR-TB: 680, XDR-TB: 4
Patients started on treatment **** MDR/RR-TB: 680, XDR-TB: 4
Treatment success rate and cohort size Success Cohort
New cases registered in 2016 90% 123 004
Previously treated cases registered in 2016    
HIV-positive TB cases registered in 2016    
MDR/RR-TB cases started on second-line treatment in 2015 75% 660
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 45%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
11% (9.9–12)
TB financing, 2018  
National TB budget (US$ millions) 93
Funding source: 11% domestic, 33% international, 56% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-26 Data: www.who.int/tb/data